Show simple item record

dc.contributor.authorKo, Darae
dc.contributor.authorMcManus, David D.
dc.contributor.authorRienstra, Michael
dc.date2022-08-11T08:09:46.000
dc.date.accessioned2022-08-23T16:42:56Z
dc.date.available2022-08-23T16:42:56Z
dc.date.issued2016-11-15
dc.date.submitted2017-03-27
dc.identifier.citationAm J Cardiol. 2016 Nov 15;118(10):1493-1496. doi: 10.1016/j.amjcard.2016.08.010. Epub 2016 Aug 24. <a href="https://doi.org/10.1016/j.amjcard.2016.08.010">Link to article on publisher's site</a>
dc.identifier.issn0002-9149 (Linking)
dc.identifier.doi10.1016/j.amjcard.2016.08.010
dc.identifier.pmid27666170
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40192
dc.description<p>Full author list omitted for brevity. For full list of authors see article.</p>
dc.description.abstractPrevious studies have shown several metabolic biomarkers to be associated with prevalent and incident atrial fibrillation (AF), but the results have not been replicated. We investigated metabolite profiles of 2,458 European ancestry participants from the Framingham Heart Study without AF at the index examination and followed them for 10 years for new-onset AF. Amino acids, organic acids, lipids, and other plasma metabolites were profiled by liquid chromatography-tandem mass spectrometry using fasting plasma samples. We conducted Cox proportional hazard analyses for association between metabolites and new-onset AF. We performed hypothesis-generating analysis to identify novel metabolites and hypothesis-testing analysis to confirm the previously reported associations between metabolites and AF. Mean age was 55.1 +/- 9.9 years, and 53% were women. Incident AF developed in 156 participants (6.3%) in 10 years of follow-up. A total of 217 metabolites were examined, consisting of 54 positively charged metabolites, 59 negatively charged metabolites, and 104 lipids. None of the 217 metabolites met our a priori specified Bonferroni corrected level of significance in the multivariate analyses. We were unable to replicate previous results demonstrating associations between metabolites that we had measured and AF. In conclusion, in our metabolomics approach, none of the metabolites we tested were significantly associated with the risk of future AF.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27666170&dopt=Abstract">Link to Article in PubMed</a>
dc.rightsOpen Access funded by VSNU.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCardiology
dc.subjectCardiovascular Diseases
dc.titleMetabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study)
dc.typeJournal Article
dc.source.journaltitleThe American journal of cardiology
dc.source.volume118
dc.source.issue10
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=3995&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/2990
dc.identifier.contextkey9928042
refterms.dateFOA2022-08-23T16:42:56Z
html.description.abstract<p>Previous studies have shown several metabolic biomarkers to be associated with prevalent and incident atrial fibrillation (AF), but the results have not been replicated. We investigated metabolite profiles of 2,458 European ancestry participants from the Framingham Heart Study without AF at the index examination and followed them for 10 years for new-onset AF. Amino acids, organic acids, lipids, and other plasma metabolites were profiled by liquid chromatography-tandem mass spectrometry using fasting plasma samples. We conducted Cox proportional hazard analyses for association between metabolites and new-onset AF. We performed hypothesis-generating analysis to identify novel metabolites and hypothesis-testing analysis to confirm the previously reported associations between metabolites and AF. Mean age was 55.1 +/- 9.9 years, and 53% were women. Incident AF developed in 156 participants (6.3%) in 10 years of follow-up. A total of 217 metabolites were examined, consisting of 54 positively charged metabolites, 59 negatively charged metabolites, and 104 lipids. None of the 217 metabolites met our a priori specified Bonferroni corrected level of significance in the multivariate analyses. We were unable to replicate previous results demonstrating associations between metabolites that we had measured and AF. In conclusion, in our metabolomics approach, none of the metabolites we tested were significantly associated with the risk of future AF.</p>
dc.identifier.submissionpathoapubs/2990
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.source.pages1493-1496


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
1_s2.0_S0002914916313704_main.pdf
Size:
153.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Open Access funded by VSNU.
Except where otherwise noted, this item's license is described as Open Access funded by VSNU.